Combination therapy cuts treatment numbers by 50%: it's official

Article

Visudyne (verteporfin) and Avastin (bevacizumab) combination therapy reduces the number of retreatments needed by half, according to Phase II study results presented at the annual Macula Society Conference in Florida, US.

Visudyne (verteporfin) and Avastin (bevacizumab) combination therapy reduces the number of retreatments needed by half, according to Phase II study results presented at the annual Macula Society Conference in Florida, US. The study, conducted in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), also showed that 30% of patients treated with combination therapy required one treatment only during the follow-up period.

Dr Michael Potter of Vancouver Hospital and the British Columbia Eye Care Centre, Canada, conducted the study to determine whether Visudyne, at low or very low fluence rates, in combination with Avastin, reduces the average number of treatments required, compared with Avastin alone. Thirty-six patients were assigned to one of three treatment groups: (1) low fluence Visudyne followed by Avastin; (2) very low fluence Visudyne followed by Avastin; and (3) Avastin alone.

Intravitreal Avastin was delivered within two hours of photodynamic therapy (PDT) at baseline. Patients returned monthly thereafter for best-corrected ETDRS visual acuity (VA) testing, optical coherence tomography (OCT), and ocular examination. Thirty per cent of the patients treated using the combination therapy required only a single combination treatment compared with Avastin monotherapy, with which all patients required additional treatments. Retreatment decisions were based primarily on OCT. PDT was administered at months zero, three, four, five or six, with a minimum three-month interval between Visudyne/sham PDT treatments.

Thirty-five patients completed the six-month visit. The average number of Avastin treatments in Group 3 was 5.1, compared with 2.8 in Group 1 and 2.4 in Group 2. Over six months, patients who were treated in the first and second treatment groups required significantly fewer treatments on average than those treated in Group 3 (p=0.005 and p<0.001, respectively). Each group experienced an average improvement in VA at month six, compared with baseline (Group 1: p>0.05; Group 2: p=0.003; and Group 3: p<0.001, respectively). Both combination therapy and monotherapy used in the study were well tolerated.

The study concluded that, in patients with subfoveal CNV secondary to AMD, a combination therapy of Visudyne followed by Avastin reduces, by half, the number of treatments required during the first six months to gain similar VA compared with Avastin monotherapy. The study was sponsored by US manufacturers of Visudyne, QLT, Inc.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.